NCT00881127View on ClinicalTrials.gov

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Allergies
Interventions
DRUG

Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)

DRUG

Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00881127 - To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter